OBX — Obsidian Therapeutics Share News
0.000.00%
Last trade - 00:00- $861.11m
- $861.11m
U.S. STOCKS ON THE MOVE-Lithia Motors, Sera Prognostics, Citigroup
Galera Therapeutics rises on FDA's priority review for oral mucositis drug
Brief: Galera Therapeutics - Expects To Report Co Had Cash And Cash Equivalents & Short-Term Investments Of About $31.6 Million As Of December 31, 2022
Brief: Galera Announces FDA Acceptance And Priority Review Of Avasopasem NDA
Brief: Galera Therapeutics Co Received Letter From Nasdaq Stating That Co Had Regained Compliance
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
Brief: Galera Submits Marketing Application For Oral Mucositis Drug
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber
Galera Therapeutics rises as co submits marketing application for oral mucositis drug
Brief: Galera Therapeutics Inc - On Dec 6, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Galera Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Galera Reports Third Quarter 2022 Financial Results
Galera Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Galera Announces Presentation Of Phase 3 Roman Long-Term Follow-Up Data At 2022 American Society For Radiation Oncology (Astro) Annual Meeting
Galera Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Galera Therapeutics reports Q2 results
Brief: Galera Announces Results From Phase 1 Stage Of Greco-1 Trial Of Rucosopasem With SBRT For NSCLC
Brief: Galera Therapeutics - On June 8, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Galera Announces Oral Presentation At 2022 American Society Of Clinical Oncology (Asco) Annual Meeting Detailing Results From Phase 3 Roman Trial Of Avasopasem